- ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase II, Open Study to Assess Efficacy and Safety of Rigosertib in Patients with Recessive Dystrophic Epidermolysis bullosa associated Locally Advanced/Metastatic Squamous Cell Carcinoma
This study is testing a new medicine, Rigosertib, for adults with a specific type of skin cancer linked to a skin condition called Recessive Dystrophic Epidermolysis Bullosa (RDEB). Doctors want to see if the medicine can shrink the cancer and if it's safe to use.
Austria - recruitingNA
Beyond TME Origins
This study looks at a new way to classify advanced bowel cancer that has come back in the pelvis. We’re using special scans to help doctors plan the best treatment and understand why cancer might return, ultimately aiming to improve care.
Norway · United Kingdom - not yet recruiting
MRinRT: Swansea University and SWWCC Collaboration Study.
This study looks at using MRI scans to make radiotherapy for cancers like brain, stomach, and gullet cancer more accurate. It aims to see if MRI can help doctors better plan and adjust treatment, potentially reducing side effects.
United Kingdom - recruiting
Anatomical-Clinical Base of Adenocarcinoma Pancreatic
This study is building a collection of samples and information from people with pancreatic cancer. It aims to help scientists better understand the disease, find new ways to spot it early, and develop more effective treatments. It's about gathering resources for future vital research.
France - active not recruitingPHASE2
Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
This study looks at a new combination of two drugs, osimertinib and savolitinib, for people with a certain type of advanced lung cancer. It's for patients whose cancer has grown worse after already taking osimertinib, to see if the new combination can help.
United States · Brazil · Canada - active not recruitingPHASE3
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
This study looks at a new combination of medicines, savolitinib and osimertinib, for people with a type of lung cancer that has gotten worse after treatment with osimertinib. It compares this new combination to standard chemotherapy to see if it works better and is safe.
United States · Argentina · Australia